CareDx, Inc. $CDNA Shares Acquired by Legal & General Group Plc

Legal & General Group Plc increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 44.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 230,482 shares of the company’s stock after acquiring an additional 70,480 shares during the period. Legal & General Group Plc owned approximately 0.45% of CareDx worth $4,342,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of CDNA. Goldman Sachs Group Inc. boosted its position in shares of CareDx by 18.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after acquiring an additional 170,504 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of CareDx by 11.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock worth $2,378,000 after acquiring an additional 13,619 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of CareDx by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock worth $1,340,000 after acquiring an additional 20,028 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of CareDx in the second quarter worth approximately $1,822,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of CareDx in the second quarter worth approximately $281,000.

Analyst Upgrades and Downgrades

CDNA has been the topic of several research analyst reports. Wells Fargo & Company raised their target price on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d)” rating on shares of CareDx in a research report on Wednesday, May 27th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. Finally, BTIG Research raised their target price on shares of CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, CareDx currently has a consensus rating of “Hold” and an average target price of $25.00.

Insider Buying and Selling

In related news, CEO John Walter Hanna, Jr. sold 10,282 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $21.12, for a total value of $217,155.84. Following the transaction, the chief executive officer owned 676,475 shares in the company, valued at approximately $14,287,152. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.40% of the company’s stock.

CareDx Stock Performance

NASDAQ CDNA opened at $21.95 on Tuesday. CareDx, Inc. has a one year low of $10.96 and a one year high of $24.02. The company’s 50 day moving average price is $20.32 and its 200 day moving average price is $19.43. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -137.19 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.11 by $0.23. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The firm had revenue of $117.70 million for the quarter, compared to analyst estimates of $102.03 million. During the same quarter last year, the firm posted $0.09 earnings per share. CareDx’s revenue for the quarter was up 39.3% compared to the same quarter last year. Sell-side analysts forecast that CareDx, Inc. will post 0.22 EPS for the current fiscal year.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.